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A B S T R A C T
Multiple sclerosis (MS) is a pathologically complex CNS disease: inflammation, demyelination, and neuroaxonal
degeneration occur concurrently and may depend on one another. Current therapies are aimed at the immune-
mediated, inflammatory destruction of myelin, whereas axonal degeneration is ongoing and not specifically
targeted. Diffusion-weighted magnetic resonance spectroscopy can measure the diffusivity of metabolites in
vivo, such as the axonal/neuronal constituent N-acetylaspartate, allowing compartment-specific assessment of
disease-related changes. Previously, we found significantly lower N-acetylaspartate diffusivity in people with MS
compared to healthy controls (Wood et al., 2012) suggesting that this technique can measure axonal degen-
eration and could be useful in developing neuroprotective agents. In this longitudinal study, we found that N-
acetylaspartate diffusivity decreased by 8.3% (p < 0.05) over 6 months in participants who were experiencing
clinical or MRI evidence of inflammatory activity (n = 13), whereas there was no significant change in N-
acetylaspartate diffusivity in the context of clinical and radiological stability (n = 6). As N-acetylaspartate
diffusivity measurements are thought to more specifically reflect the intra-axonal space, these data suggest that
N-acetylaspartate diffusivity can report on axonal health on the background of multiple pathological processes in
MS, both cross-sectionally and longitudinally.
1. Introduction
Axonal degeneration is an important direct cause of permanent
disability in multiple sclerosis (MS) (Trapp et al., 1998), making its
detection and measurement important for monitoring disease progres-
sion and therapeutic interventions. Indeed, whereas most people with
MS initially experience a disease course characterized by episodic in-
flammatory relapses followed by extended periods of remission toward
baseline function, many eventually suffer an underlying, gradual pro-
gression of neurological deficits in motor, sensory, and cognitive
function. Even with the advent of disease-modifying therapies that
decrease the incidence of inflammatory episodes, neurological function
eventually declines in most cases (Kappos et al., 2010).
The pathophysiological basis of this decline in neurological function
remains uncertain. However, examination of spinal cord tissue obtained
at autopsy from MS patients has demonstrated progressive axonal
neurofilament alterations, consistent with metabolic abnormalities, in
chronic lesions with very low microglia/macrophage activity (Schirmer
et al., 2011). Additionally, it has been found that neurodegeneration,
assessed with magnetic resonance (MR) spectroscopy and brain volume
measurements, may take place in the earliest stages of MS, in a “radi-
ologically isolated” period before the onset of clinical signs and symp-
toms (Kappos et al., 2010; Stromillo et al., 2013), as well as in a
“clinically isolated” period before people meet full diagnostic criteria
for the disease (Bergsland et al., 2012; Schirmer et al., 2011; Wattjes
et al., 2007).
In vivo MR techniques for measuring neurodegeneration in MS have
mostly focused on the end result: atrophy, which can be measured in
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both brain and spinal cord on the time scale of years (Bermel and
Bakshi, 2006; Fisher et al., 2008; Jones et al., 2013). These measure-
ments demonstrate that the rate of atrophy is accelerated in MS (De
Stefano et al., 2010) and that diminished brain volume measurements
are correlated with clinical impairment (Gao et al., 2014; Rudick et al.,
2009). Cross-sectional proton MR spectroscopy (1H MRS) studies in MS
have demonstrated low concentrations of N-acetylaspartate (NAA), an
in vivo neuroaxonal marker, within lesions, in extralesional “normal-
appearing” white matter (WM) (Choi et al., 2007), and the whole brain,
suggesting axonal loss (Ciccarelli et al., 2007; Davie et al., 1997; Filippi
et al., 2003; Ge et al., 2004; Gonen et al., 2000; Inglese et al., 2003;
Kirov et al., 2009; Leary et al., 1999; Narayana et al., 2004; Oh et al.,
2004; Pelletier et al., 2003; Rovaris et al., 2005; Suhy et al., 2000;
Tiberio et al., 2006). However, longitudinal studies in normal-ap-
pearing WM have not been able to detect declining NAA concentration
in patients with MS over a 2–3 year span (Kirov et al., 2012; Sajja et al.,
2008; Tiberio et al., 2006).
Diffusion tensor imaging (DTI) has been heavily applied in MS and
animal models of MS, with conflicting results. Most DTI studies in hu-
mans in vivo have demonstrated increased water diffusivity and de-
creased water fractional anisotropy (FA) in both lesions and normal-
appearing WM (Bammer et al., 2000; Evangelou et al., 2000; Reich
et al., 2010; Roosendaal et al., 2009; Werring et al., 1999). Fink et al.
compared DTI measures of regions derived from tractography and brain
volume analysis to distinguish the types of information contributed by
these techniques (Fink et al., 2010). Their analysis showed that whereas
both volumes and DTI values, such as FA, are loosely associated with
composite measures of disease progression, such as lesion load and the
Expanded Disability Status Scale (EDSS), they are not specific for the
underlying biological process, e.g. inflammation or neurodegeneration
(Samann et al., 2012).
In a previous cross-sectional study, we measured diffusion of NAA in the
human normal-appearing corpus callosum on a 7-Tesla (T) MRI scanner,
comparing 15 people with MS and 14 healthy controls (Wood et al., 2012).
The corpus callosum is a good location for studying axonal degeneration
from anatomical, functional, and technical standpoints: it is the largest WM
structure; it is involved in multiple sensory, attentional, and cognitive pro-
cesses; and the fibers are quasi-coherent in orientation. We found that NAA
parallel diffusivity (λ), i.e. diffusivity along the axonal propagation direction,
was on average significantly diminished in MS and, importantly, inversely
correlated with both DTI measures, i.e. mean diffusivity (MD) and fractional
anisotropy (FA), and with clinical severity (EDSS). Our findings provided
preliminary evidence that diffusion-weighted MR spectroscopy (DW-MRS)
of NAA can distinguish axonopathy from other processes such as in-
flammation, vasogenic edema, demyelination, and gliosis. Through sub-
sequent studies with healthy volunteers, we demonstrated that axonal
modeling can be used to yield NAA diffusivity values that more accurately
reflect the cytosolic diffusion coefficient of NAA while minimizing the
confounding effects of inter-subject differences and large spectroscopy
voxels (Ronen et al., 2014).
In MS, axonal degeneration plays out over time. In this study,
therefore, we asked whether the DW-MRS technique is capable of de-
tecting axonopathy in WM tissue over a period of six months. For this,
we evaluated a new cohort of MS patients that was divided into groups
with stable and active disease courses, and a third group of healthy
controls allowed us to add cross-sectional data at the two time points. In
the process, we also established that DW-MRS is feasible in a clinical
setting with a 3 T scanner.
2. Materials and methods
2.1. Participants
The National Institutes of Health Institutional Review Board ap-
proved this study. All participants gave informed consent. Participants
were neurologically evaluated in the Neuroimmunology Clinic,
National Institute of Neurological Disorders and Stroke, NIH, Bethesda,
Maryland, USA.
The MS cohort was recruited from the Neuroimmunology Clinic and
consisted of a wide range of cases – from stable cases with no new
lesions for 1–10 years (based on existing prior MRI scans) to cases with
high disease activity where new T2 lesions had formed in the 6 months
before or during the study. For this study, 19 participants who met
McDonald criteria for MS (Polman et al., 2011) were scanned. At re-
cruitment, 9 were stable – they had not had a relapse or new T2 lesion
for at least 1 year. Three of these had a new T2 lesion during the study
so were reclassified as active. Therefore, at study conclusion, there were
6 stable cases and 13 active cases. Three stable and 10 active cases were
on disease-modifying therapies.
Healthy volunteers (HVs) were recruited from the NIH Clinical
Research Volunteer Program. The HVs had no history of neurological
conditions. Each HV was examined by a neurologist and underwent
clinical MRI scans that were within normal limits. HVs were compen-
sated for taking part in the study.
All MS cases were scanned at baseline (“month 0”) and month 6.
Most active MS cases were also scanned at month 3 in order to more
closely follow disease activity. Five of the 6 HVs were scanned twice,
with scans separated by 1–14 days. For all repeat scans, volumes of
interest were positioned to match, as much as possible, the original
placement.
MS cases were assessed at month 0 and month 6 with the EDSS,
Paced Auditory Symbol Addition Test (PASAT, 3-second version), 9-
Hole Peg Test, and 25-Foot Timed Walk. By design, clinical data were
obtained within 30 days of MRI acquisition. The average time lag be-
tween MRI and clinical exam was 2 days for both stable and active
patients, with 32 of 38 scans obtained within 1 day of clinical exam and
the remaining occurring within 6, 14, 27, 28, 30 and 30 days of the
clinical exam.
During each scan session, structural and DW-MRS scans were ac-
quired for all participants. All scans were acquired on 3 T Philips
Achieva scanners (Philips Medical Systems, Best, The Netherlands) in
the NIH Clinical Center Radiology and Imaging Sciences Department.
These scanners have gradients with a maximum amplitude of 80 mT/m
and a slew rate of 100 T/m/s, quadrature volume transmit coils, and 8-
channel receive head coils.
2.2. Structural image acquisition and processing
All subjects were scanned with the following order of sequences: 3D
T1-weighted gradient echo, DTI, two DW-MRS volumes of interest
(VOIs), and a T2-weighted FLAIR. Lastly, gadolinium-enhanced T1-
weighted scans (see below) were acquired for all active MS cases and
for stable cases at the discretion of the clinician.
3D T1-weighted gradient echo images were acquired with an inversion-
prepared turbo field echo (TFE) sequence and were used for positioning of
the VOI in the DW-MRS experiments and for tissue segmentation in the
post-processing stage. Imaging parameters were: field of view (anterior-
posterior × foot-head× right-left) = 240× 240× 180 mm3, 1 mm iso-
tropic resolution, TR/TE= 7.00 ms/3.15 ms, TI = 874.2 ms,
SENSE= 2(AP) × 3(RL), and total scan time= 5.30 min+ delay for
scanner preparation. Whole brain DTI images were acquired using single-
shot 2D spin-echo echo-planar imaging. DTI parameters were: field of
view= 224× 224× 120 mm3, 2 × 2× 2mm3 isotropic resolution, TR/
TE= 7487 ms/85 ms, 32 diffusion weighting directions with b= 800 s/
mm2, SENSE= 3(AP), and total scan time= 5.50 min.
T2-weighted Fluid Attenuated Inversion Recovery (FLAIR) images were
acquired for all patient scan sessions using a 3D–FLAIR-VISTA (volume
isotropic turbo spin-echo acquisition) sequence with parameters: field of
view= 240× 240× 180 mm3, 1 mm isotropic resolution, TR/
TE= 4800 ms/365 ms, TI = 1600 ms, SENSE= 2.6(AP) × 2(RL), and
total scan time= 6.00 min. FLAIR images were acquired just prior to ac-
quisition of the final contrast-enhanced T1-weighted volume. For this
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reason, gadolinium contrast was administered during the FLAIR scan: a
single dose (0.1 mmol/kg) of gadobutrol (Gadavist; Bayer Healthcare,
Leverkusen, Germany) was injected by power injector (Medrad,
Warrendale, PA) over a period of 60 s.
T1-weighted, FLAIR and DTI volumes were processed in MIPAV
(McAuliffe et al., 2001) (Medical Image Processing, Analysis and Vi-
sualization) and JIST (Lucas et al., 2010) (Java Image Science Toolbox).
The T1-weighted and FLAIR images within an acquisition were rigidly
registered to each other and subsequently to the Montreal Neurological
Institute (MNI) atlas with the Optimized Automatic Registration (OAR)
algorithm (Jenkinson and Smith, 2001), inhomogeneity-corrected using
N3,(Sled et al., 1998) and skull-stripped with the Simple Paradigm for
Extra-Cerebral Tissue Removal (Carass et al., 2011) (SPECTRE). Tissue
segmentation into WM, gray matter (GM), deep gray structures, cere-
brospinal fluid (CSF), and lesions was performed with Lesion TOpology-
preserving Anatomy-Driven Segmentation (Bazin and Pham, 2008;
Shiee et al., 2010) (Lesion-TOADS) (IACL, Johns Hopkins University).
Lesion-TOADS is specifically adapted for segmenting the MS brain by
using a probability-based algorithm to account for the likelihood of
lesions in WM. It utilizes both the T1-weighted and FLAIR image in-
tensities, in conjunction with empirically derived statistical and topo-
logical brain atlases, to assign tissue type. We have reported that Le-
sion-TOADS-derived brain structure volumes are more strongly
associated with physical impairment in MS than those derived from
SIENAX (Shiee et al., 2010, 2012; Smith et al., 2002) (FMRIB, Oxford
University). For HVs, segmentation was performed with TOADS
without a lesion category. Two HVs did not have FLAIR images. Brain
volume values are reported as a percentage of intracranial volume
(ICV), and lesion load is calculated as a percentage of WM volume.
For the whole brain DTI images, the individual diffusion-weighted
volumes were eddy-current and motion corrected. The b = 0 s/mm2
image was registered using affine transformation to the T1-weighted
volume in MNI space with appropriate gradient-vector rotation. From
this, the diffusion tensor was estimated and diagonalized for each voxel
to yield maps of the primary eigenvector, fractional anisotropy (FA),
mean diffusivity (MD), parallel diffusivity (λ || = λ1), and perpendi-
cular diffusivity (λ⊥ = (λ2 + λ3)/2). The WM VOI mask attained from
segmentation of the T1-weighted volume was then applied to these
images to obtain eigenvectors and diffusion values corresponding to the
acquired DW-MRS VOI.
2.3. DW-MRS volume of interest & acquisition
In each session, two DW-MRS VOIs were acquired from corpus
callosum WM. The corpus callosum is a good location for studying
axonal degeneration from anatomical, functional, and technical stand-
points. The corpus callosum is centrally located, easily distinguished on
conventional MR images, and contains axons that connect corre-
sponding cortices of the right and left hemispheres. These fibers are
important for midline fusion of sensory information, coordinating in-
terhemispheric processing, and attentional control (Aboitiz and
Montiel, 2003; Banich, 1998). At the midline, the corpus callosum has
enough quasi-coherently oriented fibers to fill the relatively large voxel
that is required to generate adequate signal for diffusion weighted
spectroscopy experiments to be performed. The corpus callosum is
frequently damaged in MS, and this damage is linked to disability
(Hasan et al., 2012b; Lenzi et al., 2007; Ozturk et al., 2010; Yaldizli
et al., 2011). Alterations in quantitative MRI measures, such as DTI and
relaxometry in the corpus callosum, are associated with whole brain
measures, such as lesion load, and functional readouts, such as the EDSS
score (Hasan et al., 2012a; Reich et al., 2010).
For all participants, one VOI measured (anterior-posterior × foot-
head × right-left) 30 × 15 × 8 mm3 (3600 mm3) and was placed on
the genu and anterior body of the corpus callosum (yellow box in
Fig. 1A). The second VOI was placed on either the posterior body (16
MS, 5 HV; same dimensions as anterior corpus callosum volume) or
splenium (2 MS active, 1 MS stable, 1 HV; 12 × 15 × 18 mm3
(3240 mm3)) of the corpus callosum (green box in Fig. 1A demonstrates
splenium placement). The splenium location was chosen when the
posterior body was very thin or curved such that the VOI could not
adequately contain it, and our processing scheme specifically accounts
for varying locations across the corpus callosum.
The PRESS (Point Resolved Spectroscopy) sequence was chosen as
the base spectroscopic sequence for these single volume DW-MRS ex-
periments and was supplemented with a bipolar diffusion-weighting
scheme for minimization of eddy currents and of cross-terms with
background and imaging gradients. See Kan et al. (2012) for details and
schematic. For the diffusion weighting, two directions were chosen for
all scans: (1) a pure right-left direction in the VOI frame, which is
mostly parallel to the direction of the callosal fibers; and (2) a direction
perpendicular to the callosal fibers, forming a 45° angle between the
anterior-posterior axis and the inferior-superior axis of the VOI.
These gradient directions can be denoted in the VOI coordinates as
[1,0,0] and [0,−1,1]. The position of the gradient directions with re-
spect to the VOI is shown in Fig. 1A. In all experiments, the center
frequency was set to that of the NAA singlet peak at 2.0 ppm. Water
suppression was achieved using two frequency-selective excitation
pulses centered at the water resonance frequency, followed by de-
phasing gradients. The water suppression was “de-optimized” for the
diffusion-weighting conditions to allow sufficient residual water signal
for later use in the post-processing stage for zero-order phase correction
and frequency-drift correction of individual spectra prior to spectral
averaging. A wired peripheral pulse unit was used for cardiac syn-
chronization of the DW-MRS acquisition to minimize signal fluctuations
due to cardiac pulsation (Upadhyay et al., 2007). Pencil-beam shim-
ming was applied up to second order, resulting in a typical NAA singlet
linewidth of 7 Hz. Following each scan, a shorter scan with identical
VOI position and diffusion conditions was performed with the center
frequency set at the water resonance frequency and without water
suppression. This scan was subsequently used for eddy-current correc-
tion.
The DW-MRS parameters were: TE = 110 ms, TR = 2 cardiac cy-
cles (about 2000 ms), trigger delay = 200 ms, number of time-domain
points = 1024, spectral width = 1500 Hz, gradient duration (δ)
= 22 ms, bipolar gap = 20 ms, diffusion time (Δ) = 55 ms with 4 dif-
ferent gradient amplitudes resulting in b-values of 290, 890, 1750, and
2860 s/mm2 in the [1,0,0] direction and 650, 1760, 3460, and 5730 s/
mm2 in the [0,-1,1] direction. 48 spectra were collected for each dif-
fusion condition (2 directions, 4 b-values), plus an additional 48 for the
highest gradient in each direction. Total DW-MRS scan time ranged
from 16 to 24 min, depending upon heart rate.
2.4. DW-MRS data processing
Post-processing of the DW-MRS data was performed using custom
Matlab routines (Mathworks, Natick MA). Following DW-MRS data
acquisition, the individual spectra were first corrected for zero-order
phase fluctuations and frequency drift according to the remaining water
peak, and then eddy-current corrected using the unsuppressed water
acquisition (Upadhyay et al., 2007). Spectra were averaged within
condition, and then the remaining water peak was removed using a
Hankel Singular Value Decomposition (HSVD) method. These spectra
were quantified using LCModel using a simulated appropriate basis set
(Provencher, 1993).
The LCModel output was used as an input to a modeling routine that
calculates the intra-axonal, or cytosolic, diffusivity of NAA. This procedure is
designed to minimize the variability in the DW-MRS measurements in-
troduced by macroscopic factors, such as the position of the VOI within the
WM tract, the main direction of the tract with respect to the DW gradients,
and the macroscopic curvature of the tract within the VOI. The model,
described in Ronen et al. (2013), assumes that the diffusion-weighted NAA
signal can be decomposed into the contributions from the diffusion of NAA
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parallel and perpendicular to the axons. It also uses the angles between the
main eigenvectors of the DTI data within the DW-MRS VOI and the diffu-
sion-weighting gradient directions to account for the macroscopic curvature
of the corpus callosum within the VOI. The diffusion-weighted data in both
directions are fitted simultaneously to the model using two variables:Dcytosol
the cytosolic diffusion coefficient of NAA, and σφ, the standard deviation of
the axonal angular dispersion (Fig. 1D). Importantly, Dcytosol is independent
of the tract geometry within the VOI and thus mostly reflects the effects of
the cytosolic medium, e.g. viscosity, molecular crowding and the integrity of
intra-axonal structures, on the diffusion of NAA inside the axons.
2.5. Statistical analysis
Between-groups analyses – stable versus active or MS versus HV – of
demographic, cross-sectional, and longitudinal difference measures
were tested with mixed-effects models that account for the random
effects of each participant contributing 2 VOIs to the data set. In this
way, cross-sectional analyses were performed for each time point se-
parately. Additionally, the data for all time points together were ana-
lyzed with a mixed-effects model accounting for both the effect of
multiple time points from the same VOI and multiple VOIs from the
same participant. Data were assessed for normality based on skewness
and kurtosis. NAA Dcytosol and all DTI measures were mesokurtic,
whereas ICV was platykurtic. NAA Dcytosol and FA were approximately
symmetric. MD, λ ||, λ⊥, and ICV were negatively skewed. As the MS
and HV groups were not balanced for sex, sex was a covariate for all MS
versus HV analyses.
Longitudinal analyses consisted of calculating the difference be-
tween measures at month 6 and baseline (Δ = tmo 6 − tmo 0; a positive
difference value represents an increase at month 6). For comparison,
HV differences are shown between the first and second scans. A one-
sample Student's t-test was used to test the null hypothesis Δ = 0.
Otherwise, mixed-effects models were used to account for the random
effect of multiple VOIs. Linear regression was used to characterize as-
sociations between DW-MRS measures, DTI measures, brain volumes,
age, disease duration (measured as time since onset of symptoms at-
tributable to MS), and EDSS. The regression coefficient (RC), coefficient
of determination (R2), and p value are reported. Changes in EDSS and
25-Foot Timed Walk were evaluated with the Mann-Whitney U test.
Power and sample size calculations for DW-MRS with a similar set of
b-values at 3 T were reported previously (Wood et al., 2015). In the
present study, the goal was to establish whether DW-MRS may be worth
pursuing further as a marker of neurodegeneration. Therefore, more
type 1 errors were considered tolerable, and there was no planned
correction for multiple comparisons. Statistical analyses were per-
formed with GraphPad Prism version 6.0b for Mac OS X, GraphPad
Software, San Diego, California, USA and STATA release 11, StataCorp,
College Station, Texas, USA.
3. Results
3.1. Patient scans and demographics
Baseline demographics for all participants are shown in Table 1.
There was no significant difference between the stable and active MS
groups for age, sex, disease duration, EDSS, PASAT score, 25-Foot
Timed Walk time and 9-Hole Peg Test.
Spectra were of good quality (LCModel NAA estimates with Cramer-
Fig. 1. Voxel-of-interest localization, spectra
and model fit. A. DW-MRS voxel-of-interest
(VOI) placement on anterior corpus callosum
(yellow) and splenium (green). B. Coronal
view of anterior corpus callosum on DTI color
map overlaid with the primary eigenvector
(VOI in yellow, color denotes direction of pri-
mary eigenvector: red = right-left, green = -
anterior-posterior, blue = foot-head). C.
Diffusion weighted spectra acquired parallel
[1,0,0] to the corpus callosum fibers at 4 b-
values (s/mm2). D. Triangles: Logarithm of the
diffusion-weighted signal measured from one
active MS case with diffusion weighting ap-
plied along the parallel ([1,0,0], red) and
perpendicular ([0,-1,1], blue) directions as a
function of b-value (s/mm2). Lines: Model fit,
which yields cytosolic diffusivity Dcytosol
(σφ = the standard deviation of the axonal
angular dispersion).
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Rao Lower Bounds< 15%) for 93 of 96 DW-MRS volume acquisitions
(97%). One stable-MS and 1 active-MS patient could only tolerate ac-
quisition of one CC VOI resulting in 11 stable-MS and 25 active-MS
collected at baseline. There was month-6 follow-up for 10 of the stable-
MS and 22 of the active-MS DW-MRS VOIs (89%). As there was no
statistical difference found in DW-MRS measurements between anterior
and posterior corpus callosum VOIs, these groups were combined.
Therefore, in total there were 10 stable-MS and 22 active-MS DW-MRS
volumes with both baseline and month-6 data for longitudinal analysis.
While 6 HVs were scanned twice at baseline, the second acquisition for
one HV was unusable due to motion artifacts. Therefore, there were
10 HV DW-MRS volumes acquired at two time points. As planned for
patients with known active disease at baseline, there were 11 MS cases
with month-3 scans. For the cross-sectional analysis, all available time
points (baseline, month 3, and month 6) were averaged for each DW-
MRS volume, resulting in 10 HV, 10 stable-MS and 26 active-MS DW-
MRS measurements. All DTI-acquired water diffusivity measures are
from the same corpus callosum volumes of interest as the corresponding
DW-MRS measurements. (See Table 2.)
3.2. Cross-sectional analysis
In line with our previous findings of water and NAA diffusivity
measures in the corpus callosum in a cross-sectional study, MS patients
had lower average NAA Dcytosol (MS mean Dcytosol = 0.48 μm2/ms, HV
mean Dcytosol = 0.52 μm2/ms, p = 0.015) and higher average water
MD (MS mean MD = 1.24 μm2/ms, HV mean MD = 1.10 μm2/ms,
p = 0.004) compared to healthy volunteers (Fig. 2) (Wood et al.,
2012). In this cohort, NAA diffusivity measures were not significantly
correlated with any water diffusivity measures.
Brain volume – estimated as a percentage of total intracranial vo-
lume – was decreased in patients with MS compared to HVs (MS %
ICV = 79.8, HV %ICV = 82.0, p = 0.035) and negatively correlated
with age for both MS cases (RC =−0.11%ICV/year, R2 = 0.36,
p < 0.001) and HVs (RC = −0.12%ICV/year, R2 = 0.46, p = 0.01).
Water MD correlated negatively with %ICV for MS cases (RC =−0.03
MD/%ICV, R2 = 0.36, p < 0.001) and HVs (RC = −0.02 MD/%ICV,
R2 = 0.36, p < 0.05).
The segmentation method used here, Lesion-TOADS, was designed
for use in MS and is configured such that only lesions within WM
structures are segmented. Measurements of lesion load, both as
percentage of total WM (%WM) and as a volume (μL) within the DW-
MRS volumes of interest, demonstrated no differences between active
and stable MS groups. In the MS group, lesion load (%WM) was nega-
tively correlated with NAA Dcytosol and water FA and positively corre-
lated with water MD, λ⊥, and λ || (Supplementary Fig. 1). Disease
duration was not statistically different between stable and active MS
groups, although there was a trend toward those with the shortest
disease duration being in the active group (ns, Supplementary Fig. 2A).
3.3. Longitudinal analysis
To assess changes in diffusivity values between baseline and month
6, difference values were calculated (Δ = tmo 6 − tmo 0) for each DW-
MRS VOI; a positive value expresses an increase in a measurement over
6 months. These difference values were then compared between the
stable and active MS groups. HVs were scanned twice within 2 weeks,
not at baseline and 6 months; therefore, HV difference values are not
directly comparable to MS values and are shown only for reference
(Fig. 3). For HVs, the average difference between scans for NAA dif-
fusivity, water diffusivity, and brain volume measures were not statis-
tically different from zero nor were they different from stable or active
MS groups except for brain volume with active MS (p = 0.02).
Dcytosol difference values distinguished the stable and active MS groups –
stable mean ΔDcytosol = 0.03 μm2/ms, active mean ΔDcytosol =−0.04 μm2/
ms (p= 0.03) – primarily based on lower MSDcytosol values in active cases at
month 6 (one-sample t-test of active mean ΔDcytosol≠ 0, p= 0.01) (Fig. 3A).
ΔMD for water was also different between stable and active groups (stable
mean ΔMD=0.05 μm2/ms, active mean ΔMD=−0.03 μm2/ms,
p= 0.02), driven by an average increase in water MD values at month 6 in
stable cases (p= 0.03) (Fig. 3B). Brain volume was different between stable
and active groups (stable MS mean Δ%ICV=−0.01, active MS mean Δ%
ICV=−0.13, p=0.04; Fig. 3C). On the other hand, water fractional ani-
sotropy (Fig. 3D) did not demonstrate detectable changes over the 6-month
study period in either stable or active MS. ΔDcytosol and ΔMD were not cor-
related with disease duration (ns, Supplementary Fig. 2B).
4. Discussion
This longitudinal study, performed on a clinical 3 T MRI scanner
with standard manufacturer-provided hardware, supports the hypoth-
esis that diffusivity measurements of the intraneuronal metabolite N-
acetylaspartate may reflect the health of axons in the corpus callosum
in MS. The cross-sectional NAA diffusivity data presented here are in
agreement with those from a prior DW-MRS study of MS that was
performed on a research 7 T scanner and utilized different diffusion-
weighting parameters and a different analysis scheme (Wood et al.,
2012). In that cross-sectional study, the tensor-derived NAA parallel
diffusivity in the corpus callosum was lower in MS compared to HVs, a
finding confirmed in the present data. Additionally, in the current study
we measured NAA diffusivity in the MS corpus callosum at baseline and
month 6. We found that in cases with recent or ongoing disease activity,
cytosolic NAA diffusivity in the corpus callosum decreased at month 6
compared to baseline, even though water mean diffusivity and frac-
tional anisotropy in the same VOI did not change during this same
period. These DW-MRS data were collected on 3 T clinical scanners in a
scan time of 15–20 min per volume of interest, which was added to a
scanning session that provided clinical T1-weighted images without and
with contrast, FLAIR, and DTI.
4.1. Reproducibility and power
The reproducibility of ΔDcytosol measured with this DW-MRS tech-
nique has been demonstrated previously (Wood et al., 2015). As such,
we chose our sample size based on power calculations using this b-value
scheme and number of averages; specifically, we expected that a sample
size of 6–13 subjects per group would be sufficient to detect a between-
Table. 1
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a n = 11, as 2 MS cases were excluded: 1 uses an assistive device for walking
(25WT = 117.8 s), and 1 had an injury requiring a temporary assistive device.
b n = 8, as 5 participants declined to perform.
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group difference of 10–15%. Here, we found a difference of 14% in
ΔDcytosol between stable and active groups. The cytosolic NAA diffu-
sivity values measured here are in line with previous reports in HVs
(Ronen et al., 2014; Ronen et al., 2013; Wood et al., 2015) and ex-
periments utilizing very short diffusion times (Marchadour et al., 2012;
Najac et al., 2016). Analysis of the empirical apparent diffusion coef-
ficient (ADC) of NAA without modeling yielded similar patterns of NAA
diffusivity results, though without statistical significance. Additionally,
the increased water diffusivity measures in MS compared to HVs
(Bammer et al., 2000; Reich et al., 2010; Werring et al., 1999) and brain
volume loss in MS (Fisher et al., 2008; Gao et al., 2014) are consistent
with previous studies.
4.2. Possible relationship to underlying axonal pathology
Both the cross-sectional and longitudinal in vivo NAA diffusivity
measurements reported here follow the pattern of changes expected for
axonal degeneration. Models of molecular diffusion in cylinders
(Landman et al., 2010) predict that water diffusivity, particularly par-
allel to the long axis of axons/cylinders (λ ||), will decrease in config-
urations that occur in the setting of axonal degeneration (e.g. bulging,
broken, or crimped cylinders). Histopathological studies of degen-
erating axons have demonstrated a variety of cytosolic changes, in-
cluding alterations in neurofilament phosphorylation, mitochondrial
breakdown with release of reactive oxygen species and decreased ATP
production, and dissolution of intracellular enzymatic micro-compart-
ments (Campbell and Mahad, 2011; Carroll, 2009; Petzold et al., 2011;
Petzold et al., 2008). In principle, all of these changes could decrease
the Dcytosol due to viscosity and molecular crowding.
A subset of DTI studies in MS and related animal models have de-
monstrated decreased water λ ||. The commonality among this group is
the timing of imaging in relation to clinical symptoms or inciting
events. Animal studies, where the timing of pathology provocation is
precisely known and serial imaging is the norm, allow histopathological
verification. These studies consistently show early decreased water λ ||,
corresponding to histological evidence of axonopathy, followed by
normalized or increased water λ || and increased water λ⊥ when in-
flammation, demyelination, and gliosis become more prevalent (Budde
et al., 2009; DeBoy et al., 2007; Loy et al., 2007; Sun et al., 2006; Xie
et al., 2010). For instance, the dorsal root axotomy is an experimental
procedure for studying Wallerian degeneration in which degenerating
ascending fibers can be studied throughout their course in the spinal
cord with comparison to the intact contralateral fibers. Study of this
system at 11.7 T, with ex vivo high-resolution diffusion-weighted MRI
Table 2
Data for all time points.
Stable MS (n = 6) Active MS (n = 13) Stable vs. Active
p-value
All MS (n = 19) HVs (n = 6) MS vs. HV p-value
NAA Dcytosol (μm2/ms) All t 0.46 (0.07) 0.49 (0.07) ns 0.48 (0.07) 0.52 (0.05) 0.015
tmo 0 0.45 (0.07) 0.50 (0.07) 0.035* 0.49 (0.07)
tmo 3 0.50 (0.08)
tmo 6 0.48 (0.08) 0.47 (0.05) ns 0.47 (0.06)
DTI MD (μm2/ms) All t 1.24 (0.15) 1.23 (0.15) ns 1.24 (0.15) 1.10 (0.08) 0.004
tmo 0 1.21 (0.12) 1.24 (0.16) ns 1.23 (0.15)
tmo 3 1.24 (0.16)
tmo 6 1.27 (0.18) 1.22 (0.12) ns 1.24 (0.14)
DTI FA All t 0.55 (0.06) 0.53 (0.06) ns 0.53 (0.06) 0.57 (0.04) ns
tmo 0 0.55 (0.05) 0.53 (0.06) ns 0.54 (0.06)
tmo 3 0.53 (0.06)
tmo 6 0.54 (0.07) 0.53 (0.05) ns 0.53 (0.06)
DTI λ || (μm2/ms) All t 2.01 (0.14) 1.97 (0.15) ns 1.98 (0.14) 1.85 (0.08) < 0.0001
tmo 0 1.98 (0.11) 1.99 (0.15) ns 1.98 (0.14)
tmo 3 1.97 (0.17)
tmo 6 2.04 (0.16) 1.96 (0.12) ns 1.98 (0.14)
DTI λ⊥ (μm2/ms) All t 0. 85 (0.17) 0.86 (0.16) ns 0.86 (0.16) 0.73 (0.10) 0.0003
tmo 0 0.81 (0.14) 0.87 (0.17) ns 0.85 (0.16)
tmo 3 0.87 (0.17)
tmo 6 0.89 (0.19) 0.85 (0.13) ns 0.86 (0.15)
%ICV (%) All t 79.3 (3.3) 79.9 (1.9) ns 79.8 (2.3) 82.0 (1.4) 0.035
tmo 0 79.2 (3.3) 79.9 (1.9) ns 79.7 (2.4)
tmo 3 80.1 (2.2)
tmo 6 79.3 (3.5) 79.7 (1.8) ns 80.0 (2.4)
Lesion load (ml|%WM)a All t 6.5|1.3 8.5|1.7 ns 8.1 | 1.6 0 NA
tmo 0 6.6|1.4 8.9|1.8 ns 8.2 | 1.6
tmo 3 8.7|1.8
tmo 6 6.3|1.3 8.0|1.6 ns 7.5|1.5
VOI lesion load (mm3) All t 30 (59) 45 (62) ns 42 (62) 0 NA
tmo 0 37 (65) 50 (69) ns 46 (67)
tmo 3 51 (66)
tmo 6 22 (53) 35 (53) ns 31 (53)
Means with standard deviations in parentheses.
a For lesion load, values reported are mean absolute volume in milliliters and percent of white matter volume (without SD).
Fig. 2. Cytosolic NAA diffusivity and water mean diffusivity for healthy volunteers and
MS cases. *p < 0.05. Bars show group mean and 95% confidence interval.
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analyzed by both conventional DTI and q-space DWI methods (Farrell
et al., 2010; Zhang et al., 2009), demonstrated decreased water λ || at 3
and 30 days post-axotomy. These changes were seen in conjunction
with histological evidence of axon injury and degeneration, such as
neurofilament phosphorylation state and the presence of myelin ovoids.
This pattern of DTI changes is also borne out in the human epilepsy and
optic neuritis studies that benefitted from a known time course due to
surgical intervention and discrete clinical onset, respectively (Concha
et al., 2006; Naismith et al., 2012). Since cerebral MS lesions are often
silent, imaging studies are usually done without knowledge of, or re-
spect to, their onset. Therefore, axonopathy is always found in a mixed
setting of inflammation, edema, demyelination, and remyelination.
In the present study, we took advantage of the known increased rate
of axonopathy seen in active inflammatory MS, hypothesizing that we
would observe decreasing Dcytosol over a 6-month period. This hy-
pothesis was borne out, but interestingly we also found that the an-
nualized rate of change of water MD in the corpus callosum in the
whole MS group was 0.13% (Fig. 3B). Relative to acute lesions, chronic
lesions usually demonstrate a paucity of frank inflammation but may
still be associated with ongoing demyelination and neurodegeneration,
which can be especially pronounced in progressive MS (Frischer et al.,
2009; Frischer et al., 2015; Lassmann, 2014). These processes might
nonspecifically increase water MD in a centrally located and well-
connected brain region such as the corpus callosum.
4.3. Limitations
Further assessment in a larger cohort over a longer duration could
clarify whether our results are generalizable. At present, general-
izability is limited by the relatively small sample size of both patients
and HVs, as well as aspects of the study design. Due to the evolution of
several initially stable MS cases into the active group, the groups be-
came unbalanced, with only 6 MS cases remaining in the stable group.
Additionally, we did not scan the spinal cord, which means that we
might have missed new lesions even in the stable cases. The location
and characteristics of lesions in the active group, and the treatment
status in both groups, were heterogeneous. Scanner stability was not
assessed over time. There were no month-6 scans for HVs (the HVs were
scanned twice within 2 weeks), which means that HV data cannot be
used as reference for the longitudinal progression of neurodegenerative
processes but only as a marker of reproducibility of the method.
To partially address these limitations, data collected from anterior
and posterior corpus callosum voxels were merged. This merging may
have introduced regional and inter-individual biases. Mixed-effects re-
gression was employed to mitigate this possible effect on the statistical
models. Additionally, the anterior and posterior VOI data were ex-
amined separately in initial analyses. Overall, the separate VOIs de-
monstrated similar overall trends but were not statistically significant
on their own. Although it will require further confirmation, the fact that
VOI placement is not severely restricted with this technique may be a
strength, though care should be taken to ensure that fiber direction
within each VOI remains relatively homogeneous.
In general, MR spectroscopy measurements, and especially DW-MRS
data, are limited by a low metabolite concentration compared to water.
This means that NAA diffusivity measurements have a low signal-to-
noise ratio compared to DTI and are therefore less sensitive than water
MRI for picking up disease-related changes. The use of cardiac gating
and associated variability in TR times could lead to partial and variable
T1 saturation. Additionally, the requirement for a large VOI, imposed
by low signal-to-noise, puts DW-MRS at risk for partial-volume effects
and make it a very challenging technique for assessment of other
clinically eloquent WM tracts (e.g. corticospinal tract). On the other
hand, detailed analysis of the reliability and reproducibility of our DW-
MRS technique demonstrated that this study was adequately powered
to detect the differences in Dcytosol found here (Wood et al., 2015).
4.4. Future directions
Our data suggest that Dcytosol is more specific for axon-related
changes, and hence more sensitive to axonopathy, than its water
counterparts. For instance, the ΔNAA Dcytosol values of the stable and
active MS cases greatly overlap, even though the groups were com-
pletely segregated by the presence or absence of new T2 lesions. DTI
was no better than DW-MRS at determining disease activity, implying
that DW-MRS measurements must be evaluated in the context of other
neuroimaging and clinical data. For instance, DW-MRS cannot – and
should not – take the place of high-resolution and tract-based techni-
ques, such as DTI, which can provide whole brain and whole tract
Fig. 3. Difference values (Δ) between baseline and
month 6 for stable and active MS cases. A. Cytosolic NAA
diffusivity, *p < 0.05 for stable ≠ active, *p < 0.05
for active ≠ 0. B. Water mean diffusivity (MD),
*p < 0.05 for stable ≠ active, *p < 0.05 for
stable ≠ 0. C. Brain volume (% = total brain/total in-
tracranial volume), *p < 0.05 for stable ≠ active,
**p < 0.005 for active ≠ 0, *p < 0.05 for active ≠ -
healthy. D. Water fractional anisotropy, ns. For MS pa-
tient, Δ = tmo 6 − tmo 0 such that a positive difference
value represents an increase at month 6. For healthy
controls, scans were< 39 days apart, and the group
mean with 95% confidence interval is shown for re-
ference.
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measures of WM structure. For instance, in a recent paper, Caligiuri
et al. (2015) found that relatively specific measures of clinical pro-
gression (EDSS vs. Cognitive testing) were better correlated with
changes in DTI measures localized to functionally related CC fibers than
to measures of atrophy in those regions of the CC. They suggest that DTI
measurements may be detecting an earlier “marker of fiber damage that
has not yet resulted in macroscopic atrophy.”(Caligiuri et al., 2015).
DWS contributes complementary information to this approach. There-
fore, future studies should continue to investigate the relationship be-
tween these measures.
5. Conclusion
In summary, DW-MRS is a powerful technique that yields biologi-
cally interpretable data regarding the downstream effects of acute in-
flammatory demyelination and that can be applied in a clinical setting.
Through its compartmental specificity, DW-MRS of NAA may provide
answers to questions that are difficult to address with more conven-
tional MRI techniques.
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